FOR IMMEDIATE RELEASE National Forum for Heart Disease & Stroke Prevention Announces New Chair of Value & Access Initiative WASHINGTON, DC, July 25, 2019 – The National Forum for Heart Disease & Stroke Prevention announced that Michael Cropp, MD, MBA, President & CEO of Independent Health will serve as the Chair of the …
Immediate Past National Forum Board Chair, Dr. Jennifer Robinson, lead author on Updated Guidance from the NLA Identifying Patients in Which PCSK9i Use Provides Reasonable Value
During it's 2019 Scientific Sessions, the National Lipid Association (NLA) released a statement paper, led by Dr. Jennifer Robinson, Immediate Past National Forum Board Chair. The paper provides updated guidance to clinicians with identifying patient groups in which use of PCSK9 monoclonal antibodies (mAbs) provides a reasonable value. Read the …
National Forum Statement on Praluent Price Change
The National Forum issued the following statement in response to Sanofi and Regeneron’s announcement that they cut the list price of their LDL (“bad”) cholesterol-lowering treatment, Praluent, to $5,850 annually, a 60 percent reduction from the original list price. Amgen announced a similar price reduction in October 2018 on Repatha. Both Praluent …
National Forum Statement on Amgen’s Repatha Price Change
The National Forum issued the following statement in response to Amgen's announcement that it cut the price of its cholesterol-lowering drug, Repatha, by 60 percent. Leaders representing patients, providers, public health, payers and pharma/biotech have joined forces through the National Forum Value & Access Initiative to enhance health and …
New York Times Article: These Cholesterol-Reducers May Save Lives. So Why Aren’t Heart Patients Getting Them?
10/2/18 - New York Times article …
Value & Access Steering Committee & Partners Comment on ICER Draft Scope for Review of Canakinumab’s ASCVD Indication
A summary of feedback from the National Forum's Value & Access Initiative Steering Committee and partners engaged in the value & access space on the Institute for Clinical and Economic Review (ICER)'s draft scope for review of canakinumab's ASCVD indication View the document …
New report: Medication adherence plays critical role in heart disease disparities among blacks
Not taking prescribed medicine plays critical role in blood pressure and heart disease disparities, according to new report from FDA and National Forum for Heart Disease & Stroke Prevention Authors find non-adherence to be a ‘driving force’ behind racial/ethnic disparities in cardiovascular disease, suggest strategies to address problem The …
Value & Access Steering Committee Comments on ICER New Evidence Update
A summary of feedback from the National Forum's Value & Access Initiative Steering Committee and partners engaged in the value & access space on the Institute for Clinical and Economic Review (ICER)'s June 13th PCSK9 Inhibitors for High Cholesterol - New Evidence Update (clinical portion). August 11, 2017 Mr. Matt …
When Cholesterol Drugs Cost $14,000, an Insurance Tug-of-War
Wall Street Journal, June 19, 2017 …